Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB.

J Virol. 2009 May;83(9):4624-30. doi: 10.1128/JVI.02335-08.

2.
3.

Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.

Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K.

Immunology. 2008 Jun;124(2):155-65. doi: 10.1111/j.1365-2567.2007.02745.x.

4.

DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus.

Szécsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset FL.

J Infect Dis. 2009 Jul 15;200(2):181-90. doi: 10.1086/599840.

PMID:
19505256
5.
6.

Electroporation at low voltages enables DNA vaccine to provide protection against a lethal H5N1 avian influenza virus challenge in mice.

Zhou Y, Fang F, Chen J, Wang H, Chang H, Yang Z, Chen Z.

Intervirology. 2008;51(4):241-6. doi: 10.1159/000156483.

PMID:
18812697
7.

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2009 Feb 1;199(3):405-13. doi: 10.1086/595984.

PMID:
19061423
8.

Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.

Holman DH, Wang D, Raja NU, Luo M, Moore KM, Woraratanadharm J, Mytle N, Dong JY.

Vaccine. 2008 May 19;26(21):2627-39. doi: 10.1016/j.vaccine.2008.02.053.

PMID:
18395306
9.

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB.

PLoS One. 2008 Jun 25;3(6):e2517. doi: 10.1371/journal.pone.0002517.

10.

Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.

Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, Li Y, Wang X, Ge J, Bu Z, Chen H.

Antiviral Res. 2007 Sep;75(3):234-41.

PMID:
17451817
12.

A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.

Wu Q, Fang L, Wu X, Li B, Luo R, Yu Z, Jin M, Chen H, Xiao S.

Mol Immunol. 2009 Jul;46(11-12):2210-7. doi: 10.1016/j.molimm.2009.04.017.

PMID:
19446339
13.

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

Park KS, Lee J, Ahn SS, Byun YH, Seong BL, Baek YH, Song MS, Choi YK, Na YJ, Hwang I, Sung YC, Lee CG.

Virology. 2009 Dec 20;395(2):182-9. doi: 10.1016/j.virol.2009.09.018.

14.

Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model.

Shen X, Söderholm J, Lin F, Kobinger G, Bello A, Gregg DA, Broderick KE, Sardesai NY.

Vaccine. 2012 Nov 6;30(48):6946-54. doi: 10.1016/j.vaccine.2012.02.071.

PMID:
22406460
15.

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

Vaccine. 2009 Oct 23;27(45):6296-9. doi: 10.1016/j.vaccine.2009.03.020.

PMID:
19840663
16.

Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.

Wu J, Zhang F, Fang F, Chang H, Wang F, Yang Z, Sun B, Chen Z.

Vaccine. 2010 Mar 24;28(15):2775-81. doi: 10.1016/j.vaccine.2010.01.037.

PMID:
20117261
17.

A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.

Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H.

Vaccine. 2008 Jan 24;26(4):562-72. doi: 10.1016/j.vaccine.2007.11.031.

PMID:
18164788
18.

Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J.

J Clin Virol. 2004 Dec;31 Suppl 1:S99-106.

PMID:
15567101
19.
20.

In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine.

Jazi MH, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM.

Virus Res. 2012 Aug;167(2):219-25. doi: 10.1016/j.virusres.2012.05.002.

PMID:
22609252

Supplemental Content

Support Center